1. Invirase
2. Monomethanesulfonate, Saquinavir
3. Ro 31 8959
4. Ro 31-8959
5. Ro 318959
6. Saquinavir
7. Saquinavir Monomethanesulfonate
8. Saquinivir
1. 149845-06-7
2. Invirase
3. Fortovase
4. Saquinavir Mesilate
5. Saquinavir, Mesylate
6. Ro 31-8959/003
7. Saquinavir Methanesulfonate Salt
8. Uhb9z3841a
9. Butanediamide, N1-[(1s,2r)-3-[(3s,4as,8as)-3-[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1h)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-, (2s)-, Methanesulfonate (1:1)
10. Chebi:32121
11. (2s)-n-[(2s,3r)-4-[(3s,4as,8as)-3-(tert-butylcarbamoyl)-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-(quinoline-2-carbonylamino)butanediamide;methanesulfonic Acid
12. (s)-n1-((2s,3r)-4-((3s,4as,8as)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1h)-yl)-3-hydroxy-1-phenylbutan-2-yl)-2-(quinoline-2-carboxamido)succinamide Methanesulfonate
13. Ncgc00091469-01
14. Ro-318959003
15. Dsstox_cid_3835
16. Ro-31-8959/003
17. Saquinavir Mesilate (jan)
18. Dsstox_rid_77202
19. Dsstox_gsid_23835
20. Saquinavir Mesilate [jan]
21. Saquinavir Mesylate [usan]
22. Saquinavir Monomethanesulfonate Salt
23. Unii-uhb9z3841a
24. Saquinavir Mesylate [usan:usp]
25. Invirase (tn)
26. N1-{(1s,2r)-1-benzyl-3-[(3s,4as,8as)-3-[(tert-butylamino)carbonyl]octahydroisoquinolin-2(1h)-yl]-2-hydroxypropyl}-n2-(quinolin-2-ylcarbonyl)-l-aspartamide Methanesulfonate (salt)
27. Cas-149845-06-7
28. Saquinavir Mesylate (aids Initiative)
29. Sqv
30. Saquinavir Mesylate (usp)
31. Saquinavir Mesylate- Bio-x
32. Schembl42352
33. (s)-n-((alphas)-alpha-((1r)-2-((3s,4as,8as)-3-(tert-butylcarbamoyl)octahydro-2(1h)-isoquinolyl)-1-hydroxyethyl)phenethyl)-2-quinaldamidosuccinamide Monomethanesulfonate (salt)
34. Mls001401395
35. Chembl282042
36. Dtxsid9023835
37. Hms1571o10
38. Hms2051d04
39. Hms2098o10
40. Hms2231c15
41. Hms3715o10
42. Saquinavir Mesylate [vandf]
43. Saquinavir Mesilate [mart.]
44. Tox21_111137
45. Tox21_202533
46. Saquinavir Mesilate [who-dd]
47. Saquinavir Mesilate [who-ip]
48. Saquinavir Mesylate [usp-rs]
49. Akos015962362
50. Ac-1333
51. Ccg-100992
52. Ks-1110
53. Nc00242
54. Ncgc00260082-01
55. Saquinavir Mesylate [orange Book]
56. (2s)-n1[(1s,2r)-3-[(3s,4as,8as)-3-[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2-(1h)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]butanediamide Mesylate
57. Bs164392
58. Butanediamide, N(sup 1)-(3-(3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1h)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (3s-(2(1r*(r*),2s*),3alpha,4abeta,8abeta))-, Monomethanesulfonate (salt)
59. Butanediamide, N1-((1s,2r)-3-((3s,4as,8as)-3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1h)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (2s)-, Monomethanesulfonate (salt)
60. R-56
61. Saquinavir Mesilate [ep Monograph]
62. Saquinavir Mesylate [usp Impurity]
63. Smr000469290
64. Saquinavir Mesylate [usp Monograph]
65. Saquinavir Methanesulfonate Salt [mi]
66. Ro-31-8959-003
67. Saquinavir Mesylate, >=98% (hplc), Powder
68. D01160
69. 845s067
70. Sr-01000763454
71. J-008634
72. Sr-01000763454-4
73. Q27114794
74. Saquinavir Mesilate, European Pharmacopoeia (ep) Reference Standard
75. Saquinavir Mesylate, United States Pharmacopeia (usp) Reference Standard
76. Saquinavir For System Suitability, European Pharmacopoeia (ep) Reference Standard
77. (2s)-n1-[(1s,2r)-3-[(3s,4as,8as)-3-[[(1,1-dimethylethyl)amino]carbonyl]octahydro-2(1h)-isoquinolinyl]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]butanediamide Methanesulfonate
78. (s)-n-((.alpha.s)-.alpha.-((1r)-2-((3s,4as,8as)-3-(tert-butylcarbamoyl)octahydro-2(1h)-isoquinolyl)-1-hydroxyethyl)phenethyl)-2-quinaldamidosuccinamide Monomethanesulfonate
79. (s)-n-((.alpha.s)-.alpha.-((1r)-2-((3s,4as,8as)-3-(tert-butylcarbamoyl)octahydro-2(1h)-isoquinolyl)-1-hydroxyethyl)phenethyl)-2-quinaldamidosuccinamide Monomethanesulphonate
80. Butanediamide, N(sup 1)-(3-(3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1h)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (3s-(2(1r*(r*),2s*),3.alpha.,4a.beta.,8a.beta.))-, Monomethanesulfonate
81. Butanediamide, N(sup 1)-(3-(3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1h)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (3s-(2(1r*(r*),2s*),3.alpha.,4a.beta.,8a.beta.))-, Monomethanesulphonate
82. N-t-butyl-decahydro-2-[2(r)-hydroxy-4-phenyl-3(s)-[[n-(2-quinolylcarbonyl)-l-asparaginyl]amino]butyl]-(4as,8as)-isoquinoline-3(s)-carboxamide Methanesulphonate
| Molecular Weight | 766.9 g/mol |
|---|---|
| Molecular Formula | C39H54N6O8S |
| Hydrogen Bond Donor Count | 6 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 13 |
| Exact Mass | 766.37238388 g/mol |
| Monoisotopic Mass | 766.37238388 g/mol |
| Topological Polar Surface Area | 230 Ų |
| Heavy Atom Count | 54 |
| Formal Charge | 0 |
| Complexity | 1230 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Invirase |
| PubMed Health | Saquinavir (By mouth) |
| Drug Classes | Antiretroviral Agent |
| Drug Label | INVIRASE brand of saquinavir mesylate is an inhibitor of the human immunodeficiency virus (HIV) protease. INVIRASE is available as light brown and green, opaque hard gelatin capsules for oral administration in a 200-mg strength (as saquinavir free ba... |
| Active Ingredient | Saquinavir mesylate |
| Dosage Form | Tablet; Capsule |
| Route | Oral |
| Strength | eq 500mg base; eq 200mg base |
| Market Status | Prescription |
| Company | Hoffman La Roche; Hoffmann La Roche |
| 2 of 2 | |
|---|---|
| Drug Name | Invirase |
| PubMed Health | Saquinavir (By mouth) |
| Drug Classes | Antiretroviral Agent |
| Drug Label | INVIRASE brand of saquinavir mesylate is an inhibitor of the human immunodeficiency virus (HIV) protease. INVIRASE is available as light brown and green, opaque hard gelatin capsules for oral administration in a 200-mg strength (as saquinavir free ba... |
| Active Ingredient | Saquinavir mesylate |
| Dosage Form | Tablet; Capsule |
| Route | Oral |
| Strength | eq 500mg base; eq 200mg base |
| Market Status | Prescription |
| Company | Hoffman La Roche; Hoffmann La Roche |
Invirase is indicated for the treatment of HIV-1-infected adult patients. Invirase should only be given in combination with ritonavir and other antiretroviral medicinal products.
Cytochrome P-450 CYP3A Inhibitors
Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP3A. (See all compounds classified as Cytochrome P-450 CYP3A Inhibitors.)
HIV Protease Inhibitors
Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. (See all compounds classified as HIV Protease Inhibitors.)
J05AE01
LOOKING FOR A SUPPLIER?
